Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TAS-102 in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy

Next Previous
Trial Profile

TAS-102 in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy

Status: Suspended
Phase of Trial: Phase II

Latest Information Update: 20 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 13 Jun 2025 Planned End Date changed from 15 May 2025 to 15 May 2027.
  • 13 Jun 2025 Planned primary completion date changed from 15 May 2025 to 15 May 2027.
  • 04 Jun 2024 Results (n=15: Between 7/22/22 and 11/7/23) assessing the feasibility and efficacy of TAS-102 therapy in patients with colorectal cancer MRD+ during surveillance (after all curative intent treatments including adjuvant chemotherapy), presented at the 60th Annual Meeting of the American Society of Clinical Oncology.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top